What is the purpose of adding a mineralocorticoid receptor antagonist in HFrEF and what monitoring is required?

• A. Reduces morbidity and mortality; monitor potassium and creatinine
• B. Reduces blood pressure; monitor sodium and potassium
• C. Improves ejection fraction; monitor electrolytes
• D. Increases diuresis; monitor urine output and BUN

Answer: (A)

Blockading the mineralocorticoid receptor in HFrEF aims to cut death and hospitalization risk by countering aldosterone’s harmful effects on the heart and vessels—reducing harmful remodeling, sodium and water retention, and fibrosis. That survival benefit is what makes adding an MRA worthwhile in heart failure therapy. Because aldosterone blockade can raise potassium and affect kidney function, the key monitoring is serum potassium and creatinine (or estimated GFR) to detect hyperkalemia or renal impairment during initiation and dose adjustments. The other ideas—primarily lowering blood pressure, directly improving ejection fraction, or increasing diuresis—aren’t the main goal or the main monitoring focus for this medication class.